Sector News

Mylan throws out Teva bid

April 28, 2015
Life sciences
As expected, Mylan’s board has unanimously and vehemently rejected Teva’s takeover offer of around $40 billion, slamming the proposal for “grossly undervaluing” the firm.
 
Following weeks of speculation, Teva finally made an official, unsolicited move on the firm last week offering $82 per Mylan share in a 50/50 cash/stock transaction.
 
The marriage, Teva said, would create a generics powerhouse with pro forma 2014 annual sales of around $30 billion, though Mylan hasn’t seemed sold on the idea from the start.
 
And today Mylan’s board said Teva’s approach contains nothing that would prompt it to depart from a “successful and longstanding standalone strategy”.
 
Lacking logic
“Teva’s proposal grossly undervalues Mylan, and would require Mylan’s shareholders to accept what we believe are low-quality Teva shares in exchange for their high-quality Mylan shares in a transaction that lacks industrial logic and carries significant global antitrust risk,” noted executive chairman Robert Coury.  
 
In a hard-hitting letter to Teva, Coury said Mylan’s board would not even enter into any discussions regarding an offer unless the starting point was “significantly in excess of $100 per share.”
 
“We also believe that the proposal does not address the serious challenges of integrating two fundamentally different and conflicting cultures under a Teva Board and leadership team with a poor record of delivering sustainable shareholder value,” he said. 
 
Teva responded by saying it remains fully committed to completing the merger.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).